Main Product
Product Name:
Catalog Number:
RARECHEM AQ C3 0050; 1,2-DIPHENYLCYCLOPROPEN-3-ONE; 2,3-DIPHENYL-2-CYCLOPROPEN-1-ONE; 2,3-DIPHENYLCYCLOPROP-2-EN-1-ONE; Diphencyprone; DIPHENYLCYCLOPROPENONE; 2,3-Diphenyl-2-cyclopropene-1-one; 2,3-Diphenyl-cycloprop-2-enone
CAS Number:
Molecular Weight:
Molecular Formula:
Chemical Structure

Related Products

Reference Reading

1.Administration of Herbal Complexes, Dangguijakyak-san (TJ-23) and Coix Seeds, for Treating Verruca Planae: A Case Report.
Byun AR1, Kwon S2, Kim S3. Explore (NY). 2016 Jan-Feb;12(1):65-7. doi: 10.1016/j.explore.2015.10.003. Epub 2015 Oct 24.
Verruca planae (VP) are warts caused by the human papillomavirus. Many patients develop resistance to the conventional therapy for these lesions. Therefore, alternative therapies are needed. We encountered a patient with VP who showed resistance to conventional therapy and was subsequently treated with Dangguijakyak-san (TJ-23; Tsumura, Japan; and Tokishakuyakusan in Japanese) and coix seed tablets with favorable outcomes. A 29-year-old woman had typical VP on her left upper extremity for >11 years. She had been receiving conventional therapies such as immunotherapy with diphenylcyclopropenone, and tretinoin and imiquimod ointments. However, her VP symptoms persisted. Therefore, she was given herbal medication therapy consisting of Dangguijakyak-san (TJ-23) and coix seeds (500mg coix seed extract; Kracie, Japan). At the four-month follow-up, the papules were found to have disappeared. Therefore, we stopped the TJ-23 + coix seed therapy.
2.Alopecia areata: Part 2: treatment.
Spano F1, Donovan JC2. Can Fam Physician. 2015 Sep;61(9):757-61.
OBJECTIVE: To provide family physicians with a background understanding of the therapeutic regimens and treatment outcomes for alopecia areata (AA), as well as to help identify those patients for whom dermatologist referral might be required.
3.Factors contributing to the treatment duration of diphenylcyclopropenone immunotherapy for periungual warts.
Park HK1, Kim JS1. Dermatol Ther. 2016 Mar;29(2):114-9. doi: 10.1111/dth.12312. Epub 2015 Nov 11.
Diphenylcyclopropenone (DPCP) immunotherapy has been shown to be efficacious for the treatment of warts, especially periungual warts for which destructive techniques are limited. However, factors affecting the duration of treatment of periungual warts have not been studied. A total of 61 patients with periungual warts who were completely cured with DPCP immunotherapy were included in this study. Age, sex, disease duration, location (fingernail, toenail, or both), number of warts, diameter of the largest wart, application number for sensitization and two types of sensitization reactions, erythema and blister index (EBI), and pruritus index were evaluated. Multiple linear regression analysis was performed to find correlations of these variables with the treatment duration. Of the nine variables, application number for sensitization (regression coefficient = 3.251 and 2.428, respectively) and EBI (regression coefficient = -9.950 and -9.694, respectively) were independent factors significantly affecting both the total duration of treatment and the duration of treatment after sensitization (p < 0.
4.Topical Immunotherapy with Diphenylcyclopropenone (DPCP) Induced Vitiligo.
Kutlubay Z, Engin B, Songur A, Serdaroglu S, Tuzun Y. J Cosmet Laser Ther. 2016 Mar 10:1-7. [Epub ahead of print]
Topical immunotherapy made by diphenylcyclopropenone (DPCP) is an alternative treatment that can be used safely and efficaciously in recalcitrant alopecia areata patients. DPCP-induced vitiligo is a rare, but documented unwanted side effect. The real mechanism of DPCP-induced-vitiligo is not well known.